37.88
전일 마감가:
$37.38
열려 있는:
$37.51
하루 거래량:
2.52M
Relative Volume:
0.79
시가총액:
$10.20B
수익:
$2.17B
순이익/손실:
$521.27M
주가수익비율:
21.40
EPS:
1.77
순현금흐름:
$633.79M
1주 성능:
+1.23%
1개월 성능:
+1.12%
6개월 성능:
-1.99%
1년 성능:
+48.14%
Exelixis Inc Stock (EXEL) Company Profile
명칭
Exelixis Inc
전화
(650) 837-7000
주소
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
EXEL을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
EXEL
Exelixis Inc
|
37.88 | 10.06B | 2.17B | 521.27M | 633.79M | 1.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
2025-06-24 | 업그레이드 | Stephens | Equal-Weight → Overweight |
2025-02-24 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
2025-01-27 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2025-01-24 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2024-12-20 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
2024-12-17 | 다운그레이드 | BofA Securities | Buy → Neutral |
2024-10-16 | 재확인 | RBC Capital Mkts | Outperform |
2024-09-19 | 개시 | UBS | Neutral |
2024-04-11 | 다운그레이드 | Barclays | Overweight → Equal Weight |
2023-12-19 | 개시 | BTIG Research | Buy |
2023-12-15 | 개시 | Citigroup | Buy |
2023-09-26 | 개시 | H.C. Wainwright | Buy |
2023-08-22 | 재확인 | Oppenheimer | Outperform |
2023-08-08 | 개시 | SVB Securities | Market Perform |
2023-07-11 | 재개 | Morgan Stanley | Equal-Weight |
2023-05-10 | 재개 | Piper Sandler | Overweight |
2023-03-09 | 개시 | Wells Fargo | Overweight |
2023-01-26 | 개시 | Credit Suisse | Outperform |
2022-10-18 | 개시 | JMP Securities | Mkt Outperform |
2022-06-24 | 개시 | BMO Capital Markets | Outperform |
2021-11-19 | 개시 | Piper Sandler | Overweight |
2021-11-03 | 재개 | Jefferies | Buy |
2021-10-07 | 개시 | Jefferies | Buy |
2021-08-06 | 재확인 | H.C. Wainwright | Buy |
2021-06-15 | 개시 | H.C. Wainwright | Buy |
2021-05-18 | 재개 | Goldman | Sell |
2021-03-31 | 개시 | Credit Suisse | Outperform |
2021-03-12 | 개시 | Wolfe Research | Outperform |
2020-03-04 | 개시 | Barclays | Overweight |
2020-01-13 | 개시 | SunTrust | Buy |
2019-11-13 | 개시 | BofA/Merrill | Buy |
2019-03-18 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
2018-09-17 | 개시 | Goldman | Neutral |
2018-09-10 | 개시 | Morgan Stanley | Underweight |
2018-05-11 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | Needham | Buy |
2017-10-17 | 재확인 | RBC Capital Mkts | Outperform |
2017-10-16 | 재확인 | SunTrust | Buy |
2017-09-22 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
2017-09-12 | 재확인 | Needham | Buy |
2017-07-14 | 개시 | SunTrust | Buy |
2017-03-31 | 개시 | Needham | Buy |
2017-03-16 | 개시 | Oppenheimer | Perform |
2017-02-28 | 다운그레이드 | Stifel | Buy → Hold |
2016-11-03 | 개시 | Deutsche Bank | Buy |
2016-10-10 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
2016-09-15 | 재확인 | Stifel | Buy |
모두보기
Exelixis Inc 주식(EXEL)의 최신 뉴스
Analyzing Exelixis Inc. with risk reward ratio chartsRisk Management & Precise Buy Zone Tips - Newser
Will Exelixis Inc. be affected by tariffs2025 Stock Rankings & Real-Time Market Sentiment Reports - خودرو بانک
Can Exelixis Inc. lead its sector in growth2025 Institutional Moves & AI Optimized Trading Strategy Guides - خودرو بانک
What drives Exelixis Inc.’s stock priceSwing Trade & Growth Focused Stock Pick Reports - خودرو بانک
Exelixis Appoints Longtime Veteran Dana T. Aftab as Head of R&D - Yahoo Finance
Is Exelixis Inc. building a consolidation baseEarnings Growth Report & Real-Time Volume Analysis - Newser
Exelixis, Inc. (EXEL): A Bull Case Theory - MSN
Can Exelixis Inc. be recession proofDividend Hike & Daily Growth Stock Investment Tips - خودرو بانک
Exelixis, Inc. (EXEL): A High-Conviction Biotech Play with Cash-Generative Momentum and a De-Risked Pipeline - AInvest
Using data models to predict Exelixis Inc. stock movementEarnings Miss & Weekly Watchlist of Top Performers - Newser
Ranking Exelixis Inc. among high performing stocks via tools2025 Trade Ideas & Weekly Hot Stock Watchlists - Newser
Is Exelixis Inc.’s growth already priced inJuly 2025 Snapshot & Weekly Top Gainers Trade List - خودرو بانک
What candlestick patterns are forming on Exelixis Inc.Market Growth Report & Risk Managed Investment Entry Signals - Newser
Price momentum metrics for Exelixis Inc. explained2025 Support & Resistance & Long-Term Safe Return Strategies - Newser
Live market analysis of Exelixis Inc.2025 Analyst Calls & Growth Focused Entry Reports - Newser
Will Exelixis Inc. benefit from AI trendsRecession Risk & Precise Trade Entry Recommendations - خودرو بانک
Merck KGaA finds its next R&D leader; Exelixis retools management team as medical chief leaves - Endpoints News
Institutional scanner results for Exelixis Inc.Weekly Stock Analysis & Short-Term Trading Alerts - Newser
Will Breakout in Exelixis Inc. Sustain Through Next WeekMarket Performance Report & Low Risk Entry Point Guides - 더경남뉴스
Is Exelixis Inc. backed by strong institutional buyingJuly 2025 Review & Safe Capital Growth Tips - خودرو بانک
Statistical indicators supporting Exelixis Inc.’s strengthWeekly Profit Summary & Daily Risk Controlled Trade Plans - Newser
What’s Exelixis Inc.’s historical returnJuly 2025 Short Interest & Stepwise Trade Execution Plans - خودرو بانک
Intraday pattern recognizer results for Exelixis Inc.2025 Institutional Moves & Safe Swing Trade Setup Alerts - Newser
Exelixis Cuts 130 Jobs as Company Shuts Down Pennsylvania Facility - AInvest
Exelixis Investigated for Misleading Statements, Shares Fall 16.8% - AInvest
Exelixis shuttering Pennsylvania site, laying off 130 employees - Seeking Alpha
EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Exelixis’ Strategic Momentum in Oncology Innovation - AInvest
Exelixis at Citi’s Biopharma Conference: Strategic Growth and Innovation - Investing.com
Is Exelixis Inc. stock bottoming outPortfolio Update Summary & Low Risk High Reward Trade Ideas - Newser
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exelixis, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-03-2025 03 - MarketScreener
Exelixis (EXEL): Leveraging ZANZA's Breakthrough and Strong Cash Flow for Long-Term Value Creation - AInvest
Exelixis Presents at 2025 Wells Fargo Healthcare Conference: Key Takeaways and Insights - AInvest
Exelixis at Wells Fargo Conference: Strategic Growth and Innovation By Investing.com - Investing.com UK
Prostate Cancer Pipeline Analysi, 2025 by DelveInsight | Pfizer, Janssen Pharmaceutical, POINT Biopharma, Tavanta Therapeutics, Exelixis, Astellas Pharma Inc., Antev, ORCA Therapeutics, Regeneron Phar - Barchart.com
Transcript : Exelixis, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-03-2025 12 - MarketScreener
Building trade automation scripts for Exelixis Inc.Rate Cut & Daily Profit Maximizing Trade Tips - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Exelixis, Inc.EXEL - cnhinews.com
Breakout Watch: Is Exelixis Inc. a play on infrastructure spendingM&A Rumor & Smart Allocation Stock Reports - خودرو بانک
Take Profit: Can Exelixis Inc. lead its sector in growthPortfolio Return Report & AI Powered Buy and Sell Recommendations - خودرو بانک
What is the earnings history of Exelixis Inc.Quarterly Trade Summary & Daily Stock Trend Reports - خودرو بانک
Sector ETF performance correlation with Exelixis Inc.2025 Analyst Calls & Consistent Profit Trade Alerts - Newser
Exelixis Inc. stock retracement – recovery analysisInflation Watch & Free Risk Controlled Daily Trade Plans - Newser
Using Bollinger Bands to evaluate Exelixis Inc.July 2025 Update & Consistent Profit Alerts - Newser
How to interpret RSI for Exelixis Inc. stockJuly 2025 Weekly Recap & Stepwise Entry/Exit Trade Alerts - Newser
Can Exelixis Inc. recover in the next quarterDollar Strength & Growth Focused Investment Plans - Newser
Exelixis gains after win in patent fight with MSN over Cabometyx - MSN
Exelixis, Inc. (EXEL) Halts Phase 3 STELLAR-305 Trial - MSN
Is Exelixis Inc. stock forming a cup and handleJuly 2025 Trade Ideas & Consistent Growth Equity Picks - خودرو بانک
How to contact the Daily Bulletin - FinancialContent
Exelixis Inc (EXEL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):